It has become clear that the COVID-19 pandemic is not like other public health crises we have faced in the last few decades. It will undoubtedly bring increased scrutiny and attention — in the regulatory, class action and business contexts — to products bearing claims of disinfectant, antiseptic, immune-boosting and similar properties. Goodwin’s Nilda Isidro, a partner in the firm’s Products Litigation and Counseling practice; Carla Karp, counsel in the firm’s Specialty Litigation practice; and Ali Siedor, an associate in the Litigation department, expect this increased scrutiny to be with us not only for the next few months, but even for the next few years, and share their expertise. Read the by-line in Law360 here.
In The Press March 26, 2020